Details for New Drug Application (NDA): 208180
✉ Email this page to a colleague
The generic ingredient in ROFLUMILAST is roflumilast. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the roflumilast profile page.
Summary for 208180
| Tradename: | ROFLUMILAST |
| Applicant: | Micro Labs |
| Ingredient: | roflumilast |
| Patents: | 0 |
Pharmacology for NDA: 208180
| Mechanism of Action | Phosphodiesterase 4 Inhibitors |
Suppliers and Packaging for NDA: 208180
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ROFLUMILAST | roflumilast | TABLET;ORAL | 208180 | ANDA | Micro Labs Limited | 42571-259 | 42571-259-05 | 500 TABLET in 1 BOTTLE (42571-259-05) |
| ROFLUMILAST | roflumilast | TABLET;ORAL | 208180 | ANDA | Micro Labs Limited | 42571-259 | 42571-259-17 | 11 BLISTER PACK in 1 CARTON (42571-259-17) / 10 TABLET in 1 BLISTER PACK (42571-259-32) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MCG | ||||
| Approval Date: | Mar 22, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MCG | ||||
| Approval Date: | Apr 18, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
